Our analysis of clinical outcomes showed that GBM patients with high expression of HK2 and PKM2 in the glycolysis related genes had shorter overall survival providing the evidence that HK2 and PKM2 constitutes important targets for GBM therapy. This evidence concerns the gene PKM and glioblastoma.